Russia's Breast Cancer Drug Market Will Reach $226 Million By 2014

Novel Agents from Roche, Pfizer and Eisai Will Command Over 20 Percent of the Total Breast Cancer Drug Market in Russia in 2014, According to a New Report from Decision Resources

Jun 30, 2010, 09:15 ET from Decision Resources

WALTHAM, Mass., June 30 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the breast cancer drug market in Russia will reach $226 million by 2014. Factors promoting the market's growth include steady increases in the incidence of postmenopausal breast cancer cases, a slight shift toward higher-cost chemotherapy regimens and increases in the use of targeted therapies following novel premium-priced product launches in the larger nonhormonal segment of the market.

"In 2009, branded drugs accounted for approximately 81 percent of total sales -- 80 percent of nonhormonal drug sales and 82 percent of hormonal drug sales," stated Decision Resources' Analyst Natalia Reoutova, M.Sc. "Increasing competition from generics over our 2009 – 2014 study period will not affect multinational companies' share of nonhormonal agents due to the anticipated launch of new therapies. However, the impact will be greater in the hormonal breast cancer therapy market, where multinational companies' sales share will decrease from 82 percent to 67 percent in 2014."

The new Emerging Markets report entitled Breast Cancer in Russia also finds that four novel agents expected to launch by the end of the 2009 – 2014 forecast period -- Roche's trastuzumab-DM1, Roche's pertuzumab, Pfizer's neratinib and Eisai's eribulin -- in addition to Abraxis's Abraxane (nanoparticle paclitaxel) will command 23 percent of the total breast cancer drug market in Russia. This will be facilitated by the recently lowered regulatory hurdle (additional domestic clinical trials are not required) and Russian physicians' receptivity to new therapies for target segments in the breast cancer market.

"Given the ease with which wealthy Russian patients can access novel therapies and Russian physicians' optimism for novel approaches in hard-to-treat patient segments (e.g., triple-negative breast cancer, metastatic breast cancer), emerging breast cancer therapies will find a limited but highly receptive market in Russia," added Ms. Reoutova.

The new report features extensive primary research of physicians and epidemiology study, with analysis of trends in four major Russian cities -- Moscow, St. Petersburg, Novosibirsk, and Ekaterinburg -- and the country overall.

About Emerging Markets Reports

Decision Resources is the FIRST and ONLY company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:


Christopher Comfort

Decision Resources

781-296-2597

ccomfort@dresources.com



SOURCE Decision Resources



RELATED LINKS

http://www.decisionresources.com